HL-60细胞

HL-60/HL-60细胞系/HL-60细胞株/HL-60人急性早幼粒细胞白血病细胞

Cell line name HL-60

Synonyms HL 60; HL.60; HL60; Human Leukemia-60

Accession CVCL_0002

Resource Identification Initiative To cite this cell line use: HL-60 (RRID:CVCL_0002)

Comments Group: Space-flown cell line (cellonaut).

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: MYC genetic alteration cell panel (ATCC TCP-1035).

Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2392-I.

Population: Caucasian.

Biotechnology: Used a source of mitochondrial DNA for USA forensic testing.

Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).

Doubling time: 16 hours (PubMed=8343448); 28 hours (PubMed=25984343); ~40 hours (DSMZ=ACC-3).

Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; PubMed=12661003; Sanger).

Omics: Array-based CGH.

Omics: Cell surface proteome.

Omics: CTCF ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: CNV analysis.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Mitochondrial genome sequenced.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Anecdotal: Established at the 60th attempt to culture human leukemia biopsies in Gallo's lab. All the preceding attempts having failed.

Misspelling: IIL-60; Note=Occasionally.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

PubMed=6945469; DOI=10.1016/0145-2126(81)90018-7

Major P.P., Griffin J.D., Minden M.D., Kufe D.W.

A blast subclone of the HL-60 human promyelocytic cell line.

Leuk. Res. 5:429-430(1981)

 

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157

Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.

Differential expression of the amv gene in human hematopoietic cells.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

 

PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059

Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.

Lineage infidelity of a human myelogenous leukemia cell line.

Blood 64:1059-1063(1984)

 

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=2858093; DOI=10.1073/pnas.82.3.790; PMCID=PMC397132

Wolf D., Rotter V.

Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Proc. Natl. Acad. Sci. U.S.A. 82:790-794(1985)

 

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.

Leuk. Res. 9:209-229(1985)

 

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).

Leuk. Res. 9:549-559(1985)

 

PubMed=3860286

Bhalla K.N., Hindenburg A.A., Taub R.N., Grant S.

Isolation and characterization of an anthracycline-resistant human leukemic cell line.

Cancer Res. 45:3657-3662(1985)

 

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Leuk. Res. 9:537-548(1985)

 

PubMed=3311197; DOI=10.1182/blood.V70.5.1233.1233

Collins S.J.

The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.

Blood 70:1233-1244(1987)

 

DOI=10.1159/000415060

Morikawa S., Harada T., Katoh T.

Heterogeneity of cellular origins in human malignant lymphoma cell line derived from histo-monocytic lineage cells.

(In book chapter) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel; Switzerland (1988)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=3422031; DOI=10.1182/blood.V71.1.242.242

Dalton W.T. Jr., Ahearn M.J., McCredie K.B., Freireich E.J., Stass S.A., Trujillo J.M.

HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.

Blood 71:242-247(1988)

 

PubMed=2545346

Hindenburg A.A., Gervasoni J.E. Jr., Krishna S., Stewart V.J., Rosado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.

Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

Cancer Res. 49:4607-4614(1989)